Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized study of GS-4997 plus prednisolone vs prednisolone alone in severe alcoholic hepatitis
2016-000821-37Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of selonsertib in alcoholic hepatitis (AH) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Primary safety endpoint. Started Sep 2016; status: completed.
02
Drugs
selonsertib
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on 2016-000821-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000821-37.